Relation between microPET imaging and rotational behavior in a parkinsonian rat model induced by medial forebrain

Limin Liu1, Wenzhong Zhang2, Xiaoli Gong2

  • 1Department of Physiology, Key Laboratory for Neurodegenerative Disorders of the Ministry of Education, Capital Medical University, Beijing 100069, PR China.

Behavioural Brain Research
|February 20, 2014
PubMed

Insights

Apomorphine-induced rotation in a rat model of Parkinson's disease correlates with both presynaptic dopamine transporter availability and postsynaptic dopamine D2 receptor density, as visualized by PET imaging.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Medical Imaging

Background:

  • Parkinson's disease is characterized by the loss of dopaminergic neurons.
  • Apomorphine (APO) challenge is used to assess dopaminergic function in parkinsonian models.
  • Medial forebrain bundle (MFB) axotomy creates a unilateral parkinsonian rat model.

Purpose of the Study:

  • To investigate the relationship between apomorphine-induced rotational behavior and pre- and post-synaptic dopaminergic function.
  • To evaluate the utility of in vivo Positron Emission Tomography (PET) imaging in a rat model of Parkinson's disease.

Main Methods:

  • Unilateral MFB axotomy in rats to induce a parkinsonian model.
  • Apomorphine (APO) challenge tests at multiple time points post-lesion.
  • MicroPET imaging using [(11)C]CFT (dopamine transporter) and [(11)C]raclopride (dopamine D2 receptors).
  • Postmortem immunohistochemistry to confirm neuronal and fiber loss.

Main Results:

  • [(11)C]CFT binding decreased progressively post-lesion, correlating non-linearly with APO-induced rotations.
  • [(11)C]raclopride binding increased significantly at 3 weeks post-lesion, correlating linearly with APO-induced rotations.
  • Immunohistochemistry confirmed nigrostriatal pathway degeneration.

Conclusions:

  • Apomorphine-induced rotational behavior reflects both presynaptic and postsynaptic dopaminergic deficits in Parkinson's disease models.
  • In vivo PET imaging is a valid tool for assessing disease progression and therapeutic targets.
  • This study supports the development of novel Parkinson's disease therapies.

Related Concept Videos